Meningococcal vaccine | Primary dose(s) | Booster dose(s) |
MenACWY (for those age 11 through 21 years)* | MenACWY (any licensed vaccine):
| MenACWY (any licensed vaccine):
|
MenB (for those age 16 through 23 years based on shared decision-making)Δ | Preferred age: 16 through 18 years Either:
| Not routinely recommended unless the person becomes at risk (eg, exposed during an outbreak, occupational risk). |
MenACWY: meningococcal groups A, C, W, and Y conjugate vaccine; MenB: serogroup B meningococcal vaccine; ACIP: Advisory Committee on Immunization Practices.
* Although the ACIP recommends routine MenACWY vaccination only for adolescents age 11 through 18 years, MenACWY may be given to persons age 19 through 21 years who have not received a dose.
¶ For unvaccinated adolescents and young adults with an underlying condition for which a 2-dose primary series of MenACWY vaccination is recommended, the second dose should be given as soon after the 8-week minimum interval as possible.
Δ Given the seriousness of meningococcal disease and efficacy and safety of available formulations, we suggest MenB for persons age 16 through 23 years.